An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IMPLANET, a medical technology company focused on vertebral implants, has announced its upcoming financial information schedule for 2023. Key dates include the publication of 2022 Full-Year Revenue on January 24, 2023 and 2022 Full-Year Results on March 7, 2023. The Annual General Meeting is set for April 18, 2023, with first-quarter revenue expected on April 25, 2023. IMPLANET operates within the orthopedic surgery sector and has been expanding its commercial presence in the U.S.
Positive
Scheduled publication of 2022 Full-Year Revenue on January 24, 2023, indicating transparency and adherence to reporting standards.
Expansion of commercial operations in the United States, potentially enhancing revenue growth opportunities.
Negative
None.
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specializing in vertebral implants, today announces its schedule for the publication of financial information for 2023Etats-Unis de son expansion commerciale aux Etats-Unis,.
Event
Dates*
2022 Full-Year Revenue
January 24, 2023
2022 Full-Year Results
March 7, 2023
Annual General Meeting
April 18, 2023
2023 First-Quarter Revenue
April 25, 2023
2023 First-Half Revenue
July 11, 2023
2023 First-Half Results
September 19, 2023
2023 Third-Quarter Revenue
October 17, 2023
(*) Subject to change. Press releases will be issued after market close.
Upcoming financial publication
2022 Full-Year Revenue, on January 24, 2023 after market
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 39 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.Implanet.com.
NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
Source: IMPLANET
FAQ
What is the date for IMPLANET's 2022 Full-Year Revenue report?
IMPLANET will publish its 2022 Full-Year Revenue on January 24, 2023.
When will IMPLANET release its financial results for 2022?
The financial results for 2022 will be released on March 7, 2023.
What is the significance of IMPLANET's commercial expansion in the U.S.?
The expansion into the U.S. market is crucial for IMPLANET as it could significantly enhance revenue growth and market reach.
When is IMPLANET's Annual General Meeting scheduled?
The Annual General Meeting for IMPLANET is set for April 18, 2023.
What are the upcoming financial publication dates for IMPLANET in 2023?
Upcoming financial publication dates include: First-Q Revenue on April 25, 2023, First-Half Revenue on July 11, 2023, and Third-Quarter Revenue on October 17, 2023.
